Opinion|Videos|August 14, 2024
Future Outlooks in the Treatment of CLL/SLL
Author(s)Mazyar Shadman, MD, MPH
Focusing on the future of CLL/SLL treatment, Mazyar Shadman, MD, MPH, discusses promising therapies in the pipeline.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What do you envision for the future of treatments in CLL/SLL?
- What emerging agents or combination regimens are in the pipeline that can further improve the treatment landscape in R/R CLL/SLL?
- What emerging agents or combination regimens are in the pipeline that can further improve the treatment landscape in R/R CLL/SLL?
Advertisement
Related to this article
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
4
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
5